Format

Send to

Choose Destination
See comment in PubMed Commons below
Psychiatry Res. 2013 Aug 15;208(3):285-7. doi: 10.1016/j.psychres.2013.04.021. Epub 2013 May 24.

Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder.

Author information

1
Sunovion Pharmaceuticals Inc, 84 Waterford Dr., Marlborough, MA 01752, USA. seth.hopkins@sunovion.com

Abstract

Responses to venlafaxine treatment in major depressive disorder were stratified by COMT genotypes (Val158Met, rs4680) in a randomized, double-blind, placebo-controlled clinical trial. Improvements in depression scores among subjects with Val/Val genotypes were larger than those in Met/Met genotypes, suggesting that venlafaxine may alter noradrenergic flux differentially according to COMT activity.

KEYWORDS:

COMT; Major depressive disorder; Venlafaxine

PMID:
23706899
DOI:
10.1016/j.psychres.2013.04.021
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center